Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective role of inhaled budesonide + formoterol in COVID-19 infection
2020-001306-35Phase 3Terminated
- Sponsor
- Direction de la Recherche Clinique et de l'Innovation
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Standard of care + budesonide + formoterol with Standard of care only (2 arms). Primary endpoint: Time to clinical improvement within 30 days. Started Mar 2020; status: terminated.
02
Drugs
budesonideformoterol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001306-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001306-35.